Newsfeed

Bei diesem Bereich handelt es sich um eine mögliche Darstellungsform der Integration von Nachrichtenquellen mit Bezug zu börsennotierten Unternehmen.
Als Präsentationsebene fungiert ein Template, dass an Kurznachrichtenservices angelehnt ist, bei dem sich Nutzer einen schnellen Überblick über aktuelle Nachrichten verschaffen können. Die Detailansichten ermöglichen bei Interesse weitergehende Recherchen.

Dieser Newsfeed ist eine Zusammenstellung aktueller Nachrichten, die aus Direktanbindungen von TopTier NewsWire-Services mit Bezug zu börsennotierten Unternehmen stammen. Dieser Feed hier dient ausschließlich Demonstrationszwecken. Sektoren-spezifische Nachrichten, Public Relations sowie Produktinformationen können über die GICS Portale > Bereich Sektor-Intelligence abgerufen werden.

US74587B1017
Filter zurücksetzen
Do you already know our new terminal view? Click here.
FIGI: BBG00BRBHVD0
PLSE
Pulse Biosciences Inc
GICS: Health Care · SECTOR: Healthcare · SUB-SECTOR: Medical Instruments & Supplies · THEMEFOLIO: $PLNG
NAME
Pulse Biosciences Inc
ISIN
US74587B1017
TICKER
PLSE
MIC
XNAS
REUTERS
PLSE.OQ
BLOOMBERG
PLSE US
Sa., 25.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking positive clinical data from its nPulse Cardiac Catheter System first-in-human feasibility study at the Heart Rhythm 2026 meeting. The late-breaking pres...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 20.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation™ (nsPFA™) energy, today announced that its nPulse™ Cardiac Catheter will be prominently featured during the Heart Rhythm Society (HRS) 2026 Annual Meeting, taking place April 23-26 in Chicago, Illinois. At HRS 2026, Pulse Bi...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 17.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced plans to host an analyst event following the presentation of its late-breaking data at the Heart Rhythm Society on April 25, 2026, in Chicago, Illinois. Management will highlight the late-bre...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 09.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced the strengthening of its executive leadership team with the appointment of Liane Teplitsky as Chief Operating Officer and expanded role of Dr. David Kenigsberg as full-time Chief Medical Office...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 07.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of nPulse™ technology using proprietary nanosecond pulsed field ablation (nsPFA™) energy, today announced enrollment of the first patients in its NANOPULSE-AF study, a prospective, multicenter, IDE pivotal clinical investigation currently evaluating the nPulse™ Cardiac Catheter System for treating...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 02.04.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced plans to present at the upcoming 25th Annual Needham Virtual Healthcare Conference. Pulse Biosciences’ Management is scheduled to present on Thursday, April 16, 2026, at 9:30 am ET. A live and...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 17.03.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), pioneer of the novel nPulse™ platform using proprietary Nanosecond Pulsed Field Ablation (nsPFA™), today announced a new strategic alignment to prioritize and accelerate the development and future commercialization of its nPulse Cardiac Catheter Ablation System. “The European feasibility data from over 150...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 12.03.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced first patient enrollments in the multi-center first-in-human feasibility study of the Company’s nPulse™ Vybrance™ Percutaneous Electrode System for treatment of...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 09.03.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced clinical data on outcomes durability from the nPulse Vybrance Percutaneous Electrode System First-in-Human ablation study of benign thyroid nodules using nsPFA ener...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 05.03.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming virtual Oppenheimer 36th Annual Healthcare MedTech & Services Conference. Pulse Biosciences’ Management is scheduled to p...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Mi., 04.03.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a podium presentation and a product theatre presentation at the Annual North American Society for Interventional Thyro...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 E...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 20.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 46th Annual TD Cowen Healthcare Conference in Boston. Pulse Biosciences’ Management is scheduled to present on Wednesday, March 4...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 19.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2025. Recent Business Highlights Endocardial Catheter AF Ablation...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 06.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), developer of the novel nPulse™ technology using proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical data from the nPulse Cardiac Catheter first-in-human feasibility study. The study demonstrates successful treatment of atrial fibrillation in...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 04.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the fourth quarter and full year 2025 after market close on Thursday, February 19, 2026. Com...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 03.02.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced its nPulse technology will be featured in a late-breaking science session and a live case transmission featuring the nPulse Cardiac Catheter integrated...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 09.01.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the appointment of Maria Sainz to its Board of Directors effective as of January 9, 2026. “We are delighted to welcome Maria to our Board of Directors...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 06.01.2026       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that late-breaking data from the nPulse Cardiac Catheter Ablation System first-in-human feasibility study in Europe has been accepted for presentation a...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 29.12.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to present at the upcoming 44th Annual J.P. Morgan 2026 Healthcare Conference in San Francisco. Pulse Biosciences’ Management is scheduled to pr...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Silent Ad
Fr., 19.12.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Comp...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 18.12.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowing Pulse Bioscienc...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 09.12.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE) (the “Company” or “Pulse Biosciences”), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced a research collaboration with The University of Texas MD Anderson Cancer Center to examine the use of the Company...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 21.11.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Co...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 06.11.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced plans to participate in two upcoming investor conferences. Stifel 2025 Healthcare Conference, in New York, New York. Management is scheduled to presen...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 05.11.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced business updates and financial results for the third quarter ended September 30, 2025. Recent Business Highlights Soft Tissue Ablation Initiated a m...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 24.10.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the enrollment of the first patient in its NANOCLAMP AF Study for the treatment of atrial fibrillation (AF). The successful first procedure was complete...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 22.10.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced it will report business updates and financial results for the third quarter 2025 after market close on Wednesday, November 5, 2025. Company management w...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 16.10.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to three new employees as equity inducement awards outside of the Co...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 10.10.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced late-breaking clinical study results from the nPulse™ Cardiac Surgical System first-in-human feasibility study at the 39th European Association for Card...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 07.10.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced the upcoming presentation of early clinical data on the treatment of atrial fibrillation (AF) using the nPulse™ Cardiac Surgical System at the 39th Euro...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 17.09.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Com...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 10.09.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) energy, today announced that the company will present clinical data on benign thyroid nodule ablation using nPulse™ Vybrance™ technology at the American Thyroid Association Ann...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mo., 08.09.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE)(the “Company” or “Pulse Biosciences”), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the U.S. Food and Drug Administration (FDA) has granted approval for the Company’s Investigational Device Exemption (IDE), allowin...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 04.09.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to two new employees as equity inducement awards outside of the Company's 2017 Equity Inc...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 02.09.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced the first successful procedures in a multicenter IRB-approved study using Pulse Biosciences’ nsPFA™ Percutaneous Electrode System for the treatment of benign thyroid nodules...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 26.08.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced a new publication in the Journal Thyroid. The First-in-Human Clinical feasibility study demonstrates the effectiveness of ablation of benign thyroid nodules using nsPFA ener...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 01.08.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 45th Canaccord Genuity Annual Growth Conference in Boston. Pulse Biosciences’ Management is scheduled to present on Wednesday, August 13,...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 29.07.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report business updates and financial results for the second quarter 2025 after market close on Tuesday, August 12, 2025. Company management will host a correspondin...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 16.07.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted to Steven T. Weber, the Company’s newly hired principal accounting officer, and to four other newly hir...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 23.05.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to four new employees as equity inducement awards outside of the Company's 2017 Equity In...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 08.05.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the first quarter ended March 31, 2025. Recent Business Highlights Soft Tissue Ablation Expanded direct commercial resources f...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Di., 06.05.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming BofA Securities 2025 Health Care Conference in Las Vegas. Pulse Biosciences’ Management is scheduled to present on Wednesday, May 14, 2025,...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 01.05.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its Nanosecond PFA technology will be featured in a presentation and a preclinical poster featuring the nsPFA Cardiac Surgical System at the American Association for Th...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 25.04.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that the Compensation Committee of its Board of Directors has granted equity awards to five new employees as equity inducement awards outside of the Company's 2017 Equity In...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 24.04.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the first quarter 2025 after market close on Thursday, May 8, 2025. Company management will host a corresponding conference call beginni...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 23.04.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced that its Nanosecond PFA technology will be featured in several presentations and a live case transmission featuring the nsPFA 360° catheter mapped with the CARTO™ 3 Mapping...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Do., 27.03.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced business updates and financial results for the fourth quarter and full year ended December 31, 2024. Recent Business Highlights Soft Tissue Ablation Announced positive p...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Mi., 26.03.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced plans to present at the upcoming 24th Annual Needham Virtual Health Care Conference. Pulse Biosciences’ Management is scheduled to present on Thursday, April 10, 2025, at 9...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink
Fr., 07.03.2025       Pulse Biosciences
US74587B1017

Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) technology, today announced it will report financial results for the fourth quarter and full year 2024 after market close on Thursday, March 27, 2025. Company management will host a corresponding confe...
Zur Nachricht
Pulse Biosciences
Charts & Research Termsheets Terminal
Permalink